Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update - Announced partnership with ProGen on development of RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity - - Phase 1 study for RT-114 expected to initiate in 2025 - - Completed...

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment ~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism...

DEADLINE ALERT for BAK and PROG: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders LOS ANGELES, Sept. 17, 2020 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...